Expertise in IBD Clinical Trial Delivery

Partnering to Deliver IBD Study Success

The clinical trial environment is very competitive with new IBD products in development and many trials already running or currently being set up. This surge in clinical trial work creates challenges with site saturation and recruitment because of the decreasing availability of sites and existing IBD patients.

PPD has experienced UC and CD trial teams who understand how to help overcome these patient recruitment challenges. We can identify and engage the right sites from our extensive global databases and utilise our established working relationships with the best sites across many countries to deliver your study.

42 IBD Phase I–III studies in the past 5 years recruiting 2000+ patients

5,500 IBD global sites in our global database with associated metrics

520+ IBD-experienced operations staff, including in-house gastroenterologists

Leader in digital solutions aiding patient centricity and flexibility in trial conduct

NAVIGATING IBD ENROLMENT

Customised approach: Experienced with Biopharma and Biotech

Surpassed industry average recruitment cycle times in the last 3 years

Expanding site footprint in the APAC region

Experience in Site Identification, Engagement and Performance

- Our established relationship with many sites provides a detailed understanding of their capabilities and ability to recruit patients
- Our sites have referral networks to maximise recruitment
- Rapid start-up through defined point of contacts and streamlined processes.
- PPD's IBD patient enrolment rate outperforms the industry average.
- Offer a range of decentralised and digital solutions to make trial participation easier and more inclusive for IBD patients, enhancing patient recruitment and retention.
- Strong experience with central endoscopy services ensuring efficiencies and timeliness of readout data
- Excellence in study management and vendors ensuring study efficiencies

New ePRO for UC and CD being assessed by FDA

The PPD Late-Stage Development Group are developing an ePRO Signs and Symptoms tool for UC and CD patients. The instrument is now being evaluated and qualified with the US FDA Regulatory Agency. It is widely recognised by Regulators and HCPs that new validated instruments are required for UC and CD trials, even though the CDAI and PRO are currently widely used. PPD's commitment to ePRO development, working with Regulators and Health Care Professionals reflects the deep knowledge and recognised expertise within the IBD disease area and trial management.

PPD has deep expertise in Ulcerative Colitis and Crohn's Disease across early development, clinical development, and post marketing studies.